Table 2.
The 1-year clinical outcomes of the study population before and after PSM, n (%)
| Outcomes | Before PSM | After PSM | ||||||
|---|---|---|---|---|---|---|---|---|
| Ticagrelor (n = 779) | Clopidogrel (n = 20,037) | χ2 values | P | Ticagrelor (n = 779) | Clopidogrel (n = 1558) | χ2 values | P | |
| NACE | 41 (5.3) | 825 (4.1) | 2.469 | 0.116 | 41 (5.3) | 79 (5.1) | 0.040 | 0.842 |
| MACCE | 24 (3.1) | 643 (3.2) | 0.040 | 0.842 | 24 (3.1) | 63 (4.0) | 1.343 | 0.246 |
| Death | 7 (0.9) | 242 (1.2) | 0.606 | 0.436 | 7 (0.9) | 19 (1.2) | 0.486 | 0.486 |
| MI | 5 (0.6) | 92 (0.5) | 0.540 | 0.463 | 5 (0.6) | 15 (1.0) | 0.630 | 0.427 |
| Stroke | 1 (0.1) | 30 (0.1) | – | 1.000 | 1 (0.1) | 4 (0.3) | – | 0.670 |
| TVR | 13 (1.7) | 325 (1.6) | 0.010 | 0.919 | 13 (1.7) | 29 (1.9) | 0.109 | 0.741 |
| All bleeding | 18 (2.3) | 195 (1.0) | 13.244 | <0.001 | 18 (2.3) | 16 (1.0) | 5.969 | 0.015 |
| BARC2–5 | 8 (1.0) | 84 (0.4) | – | 0.022 | 8 (1.0) | 6 (0.4) | – | 0.084 |
| BARC3–5 | 6 (0.8) | 60 (0.3) | – | 0.037 | 6 (0.8) | 3 (0.2) | – | 0.068 |
–: Fisher exact test. PSM: Propensity score matching; NACE: Net adverse clinical event; MACCE: Major adverse cardiac or cerebral events; MI: Myocardial infarction; TVR: Target vessel revascularization; BARC: Bleeding Academic Research Consortium.